CD27

Across TCGA pan-cancer cohorts, CD27 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD27 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CD27 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CD27 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where CD27 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.893	0.313	.006	9	view →
HNSC	OS	Median	III,IV	0.809	0.576	.027	3	view →
PDAC	OS	Median	All	0.980	0.795	.011	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CD27–LUAD (DFS)

Open the LUAD breakdown →